Yao Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yao Huang has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jiyue Wang
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
2 shared publicationsLei Ding
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
2 shared publicationsLingjie Wu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
2 shared publicationsMing Wu
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
2 shared publicationsWenjun Li
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
2 shared publicationsWenxiang Qi
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, P. R. China
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
H2O2 responsive microenvironment-tailored nanoprobe for in vivo near-infrared chemiluminescence imaging of tumor and inflammation
- 8 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Open AccessH2O2 responsive microenvironment-tailored nanoprobe for in vivo near-infrared chemiluminescence imaging of tumor and inflammation
- Open Access
- 28 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Biomimetic β-lapachone and hemin nanoassembly for intracellular oxidation cascade amplified ferroptosis in hepatocellular carcinoma therapy
Ferroptosis represents one of important no-apoptotic programmed cell death with over accumulation of iron- and reactive oxygen species (ROS). While its key role and trials for cancer therapy, achieving precise and potent induction ferroptosis in cancer cells with massive amplification of cellular lipid peroxidation and iron overloading, remains a significant hurdle. Herein, we developed a biomimetic red blood cell membranes (RBCM) camouflaged β-lapachone (Lap) and hemin nanoassembly (LHNPs@RBCM) as ferroptosis inducer for hepatocellular carcinoma (HCC) therapy. The RBCM endowed the nanoassembly with prolonged systemic circulation and improved tumor accumulation. After endocytosis of LHNPs@RBCM by cancer cells, the cancer-specific overexpressed NAD(P)H: quinone oxidoreductase (NQO1) converted the released Lap to ROS (e.g. O2.-, H2O2) with good selectivity, while hemin reacted with H2O2 and turned the less reactive H2O2 into highly reactive hydroxyl radical (·OH) by Fenton reaction. These ·OH reacted with polyunsaturated fatty acids (PUFAs), triggering lethal lipid peroxides (LPO) and subsequent ferroptosis. Additionally, the ROS induced activation of the NRF2 pathway, which in turn upregulates NQO1 and heme oxygenase 1 (HO-1), creating a positive feedback loop that further elevates H2O2 levels and labile iron pools. Due to the combination of classical GPX4 suppression pathway by ROS with a non-classical HO-1-mediated iron overload mechanism for ferroptosis, the LHNPs@RBCM effectively killed cancer cells in both cellular and animal models. The excellent therapeutic effect of LHNPs@RBCM demonstrated it as a transformative strategy for clinical ferroptosis-based therapy.
- 28 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessBiomimetic β-lapachone and hemin nanoassembly for intracellular oxidation cascade amplified ferroptosis in hepatocellular carcinoma therapy
Ferroptosis represents one of important no-apoptotic programmed cell death with over accumulation of iron- and reactive oxygen species (ROS). While its key role and trials for cancer therapy, achieving precise and potent induction ferroptosis in cancer cells with massive amplification of cellular lipid peroxidation and iron overloading, remains a significant hurdle. Herein, we developed a biomimetic red blood cell membranes (RBCM) camouflaged β-lapachone (Lap) and hemin nanoassembly (LHNPs@RBCM) as ferroptosis inducer for hepatocellular carcinoma (HCC) therapy. The RBCM endowed the nanoassembly with prolonged systemic circulation and improved tumor accumulation. After endocytosis of LHNPs@RBCM by cancer cells, the cancer-specific overexpressed NAD(P)H: quinone oxidoreductase (NQO1) converted the released Lap to ROS (e.g. O2.-, H2O2) with good selectivity, while hemin reacted with H2O2 and turned the less reactive H2O2 into highly reactive hydroxyl radical (·OH) by Fenton reaction. These ·OH reacted with polyunsaturated fatty acids (PUFAs), triggering lethal lipid peroxides (LPO) and subsequent ferroptosis. Additionally, the ROS induced activation of the NRF2 pathway, which in turn upregulates NQO1 and heme oxygenase 1 (HO-1), creating a positive feedback loop that further elevates H2O2 levels and labile iron pools. Due to the combination of classical GPX4 suppression pathway by ROS with a non-classical HO-1-mediated iron overload mechanism for ferroptosis, the LHNPs@RBCM effectively killed cancer cells in both cellular and animal models. The excellent therapeutic effect of LHNPs@RBCM demonstrated it as a transformative strategy for clinical ferroptosis-based therapy.
- Open Access
- 20 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102937
Rare-earth cerium-coordinated ICG nanoprobe for tumor hypoxia relief and intensified photodynamic therapy
- 20 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102937
Open AccessRare-earth cerium-coordinated ICG nanoprobe for tumor hypoxia relief and intensified photodynamic therapy